ClinicalTrials.gg
CompletedNCT02015793Updated May 30, 2018Results posted

Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

A Phase 2 interventional study of Adalimumab and Placebo for adalimumab in Crohn's Disease, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-05-30.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
33rd of 42
30 · median 143
Started
2013
with 2 others
Phase 2
2 of 42
none open now
Registered
25th of 42
by date
Lead sponsor
6 of 42
AbbVie

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 33rd largest by enrollment, is one of 3 that started in 2013, is one of 2 in phase 2, and was the 25th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy, safety, and pharmacokinetics of adalimumab following subcutaneous (SC) administration of 2 dosing regimens in Chinese subjects with Crohn's disease.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects of Chinese descent with full Chinese parentage.
  2. Diagnosis of Crohn's disease (CD) for at least 3 months prior to Week 0 confirmed by endoscopy, radiologic evaluation, and/or histology during the Screening Period.
  3. Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450 despite treatment with oral and/or .
  4. Subject has a negative Tuberculosis (TB) Screening Assessment.

Exclusion criteria

Exclusion Criteria:

  1. Subject with ulcerative colitis or indeterminate colitis.
  2. Subject who has had a surgical bowel resection within the past 6 months or who is planning any resection at any time point in the future.
  3. Subject with an ostomy or ileoanal pouch.
  4. Subject who has short bowel syndrome.
  5. Subject with symptomatic known obstructive strictures.
  6. Subject with an internal or external fistula (with the exception of an anal fistula without abscess).
  7. Chronic recurring infections or active TB.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Low Induction Dose

    Participants received the low loading dose of adalimumab (80 mg at Week 0) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 2, 4, and 6.

    Biological: Adalimumab · Biological: Placebo for adalimumab

  • Experimental
    Standard Induction Dose

    Participants received the standard loading dose of adalimumab (160 mg at Week 0 and 80 mg at Week 2) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 4 and 6.

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Adalimumab pre-filled syringe, administered by subcutaneous injection.

  • BiologicalPlacebo for adalimumab

    Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.

06

What researchers measure

Primary outcomes

  1. Mean Serum Adalimumab Concentration at Week 8

    Blood samples were drawn prior to drug administration. Adalimumab concentrations in serum were determined using a validated enzyme-linked immunosorbent assay (ELISA) method.

    Time frame: Week 8

Secondary outcomes

  1. Number of Participants With Potentially Significant Hematology Parameters During Administration of Adalimumab

    The number of participants with an abnormal laboratory result meeting Common Toxicity Criteria (CTC) Version 3.0 (or later) of Grade 3 or higher is summarized. n=the number of participants with CTC Grade \<3 at baseline and a post-baseline value for each parameter.

    Time frame: 26 weeks

  2. Number of Participants With Potentially Significant Clinical Chemistry Parameters During Administration of Adalimumab

    The number of participants with an abnormal laboratory result meeting Common Toxicity Criteria (CTC) Version 3.0 (or later) of Grade 3 or higher is summarized.

    Time frame: From Week 0 to Week 26

  3. Number of Participants With Potentially Significant Vital Signs Parameters During Administration of Adalimumab

    Blood pressure and pulse were measured while the participant was sitting. The number of participants with a postbaseline vital sign result that meets Common Toxicity Criteria (CTC) version 3.0 (or later) Grade 3 or higher and is also more extreme than the baseline value is summarized. Terms abbreviated in the table include systolic blood pressure (SBP) and diastolic blood pressure (DBP). Increase and decrease are signified by ↑ and ↓, respectively.

    Time frame: 26 weeks

  4. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs or TESAE) are defined as any event that began or worsened in severity after the first dose of study drug. The investigator assessed the relationship of each event to the use of study drug as either Reasonable possibility or No reasonable possibility of being related to study drug. For more details on adverse events please see the AE section below.

    Time frame: 35 weeks

  5. Percentage of Participants Who Achieved Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) Every 2 Weeks up to Week 26

    CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score of 220 to 450 reflects moderate to severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

    Time frame: Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26

  6. Percentage of Participants Who Achieved Clinical Response (CDAI Decrease ≥ 70 From Week 0) Every 2 Weeks up to Week 26

    CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score of 220 to 450 reflects moderate to severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

    Time frame: Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26

  7. CDAI: Mean Change From Baseline to Each Visit

    CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. Scores range from 0 to approximately 600. A score below 150 indicates remission and a score of 220 to 450 reflects moderate to severe disease. Last observation carried forward (LOCF) for missing CDAI observations was used.

    Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26

  8. High-sensitivity C-reactive Protein (hsCRP): Median Change From Baseline (Week 0) to Week 26

    hsCRP was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 3 mg/L, slightly increasing with age. LOCF was used for missing data.

    Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, and 26

  9. Fecal Calprotectin: Change From Baseline (Week 0) to Week 8

    Stool samples for fecal calprotectin were collected before study drug administration when possible. Decreases in calprotectin are associated with decreased inflammation in the gastrointestinal tract. LOCF was used for missing data.

    Time frame: Baseline (Week 0) and Weeks 4 and 8

Other outcomes

  1. Number of Subjects Positive for Anti-Adalimumab Antibodies (AAA) From Baseline to Week 8

    Serum samples with adalimumab concentration below 2 μg/mL were selected for AAA analyses. Samples were considered AAA positive if the measured AAA concentration was above 2 μg/mL. A subject was considered to be AAA positive if the subject had at least one AAA positive sample observed within 30 days following the subject's last adalimumab dose. No samples were tested because all samples had adalimumab concentrations \>2 μg/mL.

    Time frame: Baseline (Week 0) to Week 8

07

Results

Posted May 13, 2016

Participant flow

Participant flow — Overall Study
MilestoneLow Induction DoseStandard Induction Dose
Started1515
Completed double-blind period1414
Entered open-label extension period1314
Completed1111
Not completed44
Withdrew: Adverse event33
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryMean Serum Adalimumab Concentration at Week 8

Blood samples were drawn prior to drug administration. Adalimumab concentrations in serum were determined using a validated enzyme-linked immunosorbent assay (ELISA) method.

Time frame:
Week 8
Reported as:
Mean · μg/mL
Mean Serum Adalimumab Concentration at Week 8
μg/mLLow Induction DoseStandard Induction Dose
Mean Serum Adalimumab Concentration at Week 87.99 ± 3.4810.0 ± 4.57
SecondaryNumber of Participants With Potentially Significant Hematology Parameters During Administration of Adalimumab

The number of participants with an abnormal laboratory result meeting Common Toxicity Criteria (CTC) Version 3.0 (or later) of Grade 3 or higher is summarized. n=the number of participants with CTC Grade \<3 at baseline and a post-baseline value for each parameter.

Time frame:
26 weeks
Reported as:
Number · participants
Number of Participants With Potentially Significant Hematology Parameters During Administration of Adalimumab
participantsLow Induction DoseStandard Induction Dose
Haemoglobin <80 g/L (n=15,15)11
White Blood Cells ≥1 x10^9/L (n=15,15)10
Neutrophils <1.0x10^9/mcL (n=15,15)10
Lymphocytes <0.5x10^3/mcL (n=15,13)20
SecondaryNumber of Participants With Potentially Significant Clinical Chemistry Parameters During Administration of Adalimumab

The number of participants with an abnormal laboratory result meeting Common Toxicity Criteria (CTC) Version 3.0 (or later) of Grade 3 or higher is summarized.

Time frame:
From Week 0 to Week 26
Reported as:
Number · participants
Number of Participants With Potentially Significant Clinical Chemistry Parameters During Administration of Adalimumab
participantsLow Induction DoseStandard Induction Dose
Potassium <3.0 mmol/L01
Sodium <130 mmol/L01
Albumin <20 g/L01
Calcium <1.75 mmol/L01
Uric Acid >500µmol/L01
SecondaryNumber of Participants With Potentially Significant Vital Signs Parameters During Administration of Adalimumab

Blood pressure and pulse were measured while the participant was sitting. The number of participants with a postbaseline vital sign result that meets Common Toxicity Criteria (CTC) version 3.0 (or later) Grade 3 or higher and is also more extreme than the baseline value is summarized. Terms abbreviated in the table include systolic blood pressure (SBP) and diastolic blood pressure (DBP). Increase and decrease are signified by ↑ and ↓, respectively.

Time frame:
26 weeks
Reported as:
Number · participants
Number of Participants With Potentially Significant Vital Signs Parameters During Administration of Adalimumab
participantsLow Induction DoseStandard Induction Dose
SBP ≤90 mm Hg or ≥20 mm Hg ↓ from BL75
SBP ≥180 mm Hg or ≥20 mm Hg ↑ from BL83
DBP ≤50 mm Hg or ≥15 mm Hg ↓ from BL34
SBP ≥105 mm Hg or ≥15 mm Hg ↑ from BL64
Pulse ≤50 bpm or ≥15 bpm ↓ from BL67
Pulse SBP ≥120 bpm or ≥15 bpm ↑ from BL76
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs or TESAE) are defined as any event that began or worsened in severity after the first dose of study drug. The investigator assessed the relationship of each event to the use of study drug as either Reasonable possibility or No reasonable possibility of being related to study drug. For more details on adverse events please see the AE section below.

Time frame:
35 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsLow Induction Dose (Double-blind Period)Standard Induction Dose (Double-blind Period)Low Induction Dose (Open-label Extension Period)Standard Induction Dose (Open-label Extension)
Any TEAE6777
Any TESAE1112
TEAE leading to discontinuation2112
Severe TEAE0101
TEAEs with reasonable possibility of being related3656
Deaths0000
SecondaryPercentage of Participants Who Achieved Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) Every 2 Weeks up to Week 26

CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score of 220 to 450 reflects moderate to severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

Time frame:
Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) Every 2 Weeks up to Week 26
percentage of participantsLow Induction DoseStandard Induction Dose
Week 226.7 (7.8 to 55.1)46.7 (21.3 to 73.4)
Week 440.0 (16.3 to 67.7)66.7 (38.4 to 88.2)
Week 660.0 (32.3 to 83.7)73.3 (44.9 to 92.2)
Week 860.0 (32.3 to 83.7)66.7 (38.4 to 88.2)
Week 1066.7 (38.4 to 88.2)66.7 (38.4 to 88.2)
Week 1260.0 (32.3 to 83.7)73.3 (44.9 to 92.2)
Week 1460.0 (32.3 to 83.7)73.3 (44.9 to 92.2)
Week 1660.0 (32.3 to 83.7)73.3 (44.9 to 92.2)
Week 1860.0 (32.3 to 83.7)73.3 (44.9 to 92.2)
Week 2066.7 (38.4 to 88.2)66.7 (38.4 to 88.2)
Week 2266.7 (38.4 to 88.2)66.7 (38.4 to 88.2)
Week 2466.7 (38.4 to 88.2)66.7 (38.4 to 88.2)
Week 2666.7 (38.4 to 88.2)66.7 (38.4 to 88.2)
SecondaryPercentage of Participants Who Achieved Clinical Response (CDAI Decrease ≥ 70 From Week 0) Every 2 Weeks up to Week 26

CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score of 220 to 450 reflects moderate to severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

Time frame:
Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response (CDAI Decrease ≥ 70 From Week 0) Every 2 Weeks up to Week 26
percentage of participantsLow Induction DoseStandard Induction Dose
Week 266.7 (38.4 to 88.2)80.0 (51.9 to 95.7)
Week 493.3 (68.1 to 99.8)93.3 (68.1 to 99.8)
Week 693.3 (68.1 to 99.8)86.7 (59.5 to 98.3)
Week 893.3 (68.1 to 99.8)86.7 (59.5 to 98.3)
Week 1086.7 (59.5 to 98.3)86.7 (59.5 to 98.3)
Week 1280.0 (51.9 to 95.7)80.0 (51.9 to 95.7)
Week 1473.7 (44.9 to 92.2)73.7 (44.9 to 92.2)
Week 1680.0 (51.9 to 95.7)73.7 (44.9 to 92.2)
Week 1880.0 (51.9 to 95.7)73.7 (44.9 to 92.2)
Week 2073.7 (44.9 to 92.2)66.7 (38.4 to 88.2)
Week 2266.7 (38.4 to 88.2)66.7 (38.4 to 88.2)
Week 2466.7 (38.4 to 88.2)66.7 (38.4 to 88.2)
Week 2666.7 (38.4 to 88.2)66.7 (38.4 to 88.2)
SecondaryCDAI: Mean Change From Baseline to Each Visit

CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. Scores range from 0 to approximately 600. A score below 150 indicates remission and a score of 220 to 450 reflects moderate to severe disease. Last observation carried forward (LOCF) for missing CDAI observations was used.

Time frame:
Baseline (Week 0) and Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26
Reported as:
Mean · units on a scale
CDAI: Mean Change From Baseline to Each Visit
units on a scaleLow Induction DoseStandard Induction Dose
Week 2-108.91 ± 76.196-143.79 ± 86.193
Week 4-152.96 ± 71.589-163.21 ± 95.545
Week 6-163.53 ± 80.868-178.23 ± 103.159
Week 8-181.50 ± 81.611-181.87 ± 100.077
Week 10-185.24 ± 81.532-182.87 ± 96.039
Week 12-200.33 ± 88.612-191.09 ± 98.035
Week 14-193.63 ± 97.130-194.96 ± 111.444
Week 16-198.07 ± 96.381-191.37 ± 108.932
Week 18-200.17 ± 93.758-188.31 ± 109.516
Week 20-214.43 ± 96.417-189.83 ± 110.845
Week 22-213.95 ± 98.357-194.53 ± 111.046
Week 24-215.47 ± 99.278-187.98 ± 107.702
Week 26-215.79 ± 101.879-200.17 ± 110.999
SecondaryHigh-sensitivity C-reactive Protein (hsCRP): Median Change From Baseline (Week 0) to Week 26

hsCRP was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 3 mg/L, slightly increasing with age. LOCF was used for missing data.

Time frame:
Baseline (Week 0) and Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, and 26
Reported as:
Median · mg/L
High-sensitivity C-reactive Protein (hsCRP): Median Change From Baseline (Week 0) to Week 26
mg/LLow Induction DoseStandard Induction Dose
Week 1-7.70 (-74.8 to 28.1)-24.51 (-187.6 to -1.7)
Week 2-14.10 (-83.3 to 32.3)-25.37 (-184.7 to 5.3)
Week 4-12.05 (-93.2 to 42.2)-21.12 (-170.6 to 43.0)
Week 6-12.66 (-94.6 to 46.2)-21.61 (-165.9 to 18.2)
Week 8-11.90 (-98.9 to 13.0)-21.58 (-165.1 to 12.9)
Week 12-9.40 (-114.9 to 17.6)-15.00 (-188.3 to 50.5)
Week 16-14.00 (-101.1 to 0.8)-15.10 (-191.1 to 33.7)
Week 20-9.50 (-108.5 to 0.1)-12.80 (-194.2 to 21.5)
Week 24-12.90 (-112.4 to 13.7)-12.90 (-194.6 to 32.5)
Week 26-11.20 (-103.4 to 16.8)-6.90 (-194.6 to 22.5)
SecondaryFecal Calprotectin: Change From Baseline (Week 0) to Week 8

Stool samples for fecal calprotectin were collected before study drug administration when possible. Decreases in calprotectin are associated with decreased inflammation in the gastrointestinal tract. LOCF was used for missing data.

Time frame:
Baseline (Week 0) and Weeks 4 and 8
Reported as:
Median · μg/g
Fecal Calprotectin: Change From Baseline (Week 0) to Week 8
μg/gLow Induction DoseStandard Induction Dose
Week 4-135.0 (-1441 to 3397)-207.0 (-1334 to 3410)
Week 8-44.0 (-1926 to 5632)-274.0 (-915 to 6213)
Other pre-specifiedNumber of Subjects Positive for Anti-Adalimumab Antibodies (AAA) From Baseline to Week 8

Serum samples with adalimumab concentration below 2 μg/mL were selected for AAA analyses. Samples were considered AAA positive if the measured AAA concentration was above 2 μg/mL. A subject was considered to be AAA positive if the subject had at least one AAA positive sample observed within 30 days following the subject's last adalimumab dose. No samples were tested because all samples had adalimumab concentrations \>2 μg/mL.

Time frame:
Baseline (Week 0) to Week 8

No measurements were reported for this outcome.

Adverse events

Collected over Treatment-emergent AEs (TEAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 35 weeks); SAEs were collected from the time informed consent was obtained (39 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Induction Dose (Double-blind)—1/15 (6.7%)6/15 (40%)
Standard Induction Dose (Double-blind)—1/15 (6.7%)7/15 (46.7%)
Low Induction Dose (Open-label Extension)—1/13 (7.7%)6/13 (46.2%)
Standard Induction Dose (Open-label Extension)—2/14 (14.3%)6/14 (42.9%)
Most frequent serious events
Most frequent serious events
EventLow Induction Dose (Double-blind)Standard Induction Dose (Double-blind)Low Induction Dose (Open-label Extension)Standard Induction Dose (Open-label Extension)
CROHN'S DISEASEGastrointestinal disorders1/151/150/132/14
MYCOBACTERIUM TUBERCULOSIS COMPLEX TEST POSITIVEInvestigations0/150/151/130/14
INTESTINAL OBSTRUCTIONGastrointestinal disorders0/151/150/130/14
LUNG INFECTIONInfections and infestations0/151/150/130/14
TUBERCULOSIS GASTROINTESTINALInfections and infestations0/151/150/130/14
Most frequent other events
Showing 10 of 41
Most frequent other events
EventLow Induction Dose (Double-blind)Standard Induction Dose (Double-blind)Low Induction Dose (Open-label Extension)Standard Induction Dose (Open-label Extension)
LEUKOPENIABlood and lymphatic system disorders3/151/152/131/14
MYCOBACTERIUM TUBERCULOSIS COMPLEX TEST POSITIVEInvestigations0/150/150/132/14
PYREXIAGeneral disorders2/151/150/131/14
ALANINE AMINOTRANSFERASE INCREASEDInvestigations0/152/150/130/14
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations0/152/150/131/14
APHTHOUS STOMATITISGastrointestinal disorders0/150/151/130/14
GASTROENTERITISInfections and infestations0/150/151/130/14
PHARYNGITISInfections and infestations0/150/151/130/14
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/150/151/130/14
ANIMAL BITEInjury, poisoning and procedural complications0/150/151/130/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Low Induction DoseStandard Induction DoseTotal
Mean33.5 ± 14.6035.6 ± 13.0034.5 ± 13.63
Sex: Female, Male
Sex: Female, Male(Participants)Low Induction DoseStandard Induction DoseTotal
Female246
Male131124
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Wu KC, Ran ZH, Gao X, Chen M, Zhong J, Sheng JQ, Kamm MA, Travis S, Wallace K, Mostafa NM, Shapiro M, Li Y, Thakkar RB, Robinson AM. Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease. Intest Res. 2016 Apr;14(2):152-63. doi: 10.5217/ir.2016.14.2.152. Epub 2016 Apr 27. PubMed 27175116 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2013
First posted
Dec 19, 2013
Start
Dec 2013
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results first posted
May 13, 2016
Last update
May 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02015793
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 19, 2013
Start date
Dec 2013
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
May 13, 2016
Last update
May 30, 2018

Study contacts

Anne Robinson
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion